B
Byoung Chul Cho
Researcher at Yonsei University
Publications - 570
Citations - 23868
Byoung Chul Cho is an academic researcher from Yonsei University. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 57, co-authored 429 publications receiving 15603 citations. Previous affiliations of Byoung Chul Cho include University Health System & AstraZeneca.
Papers
More filters
Journal ArticleDOI
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
David Spiegel,Corinne Faivre-Finn,Jhanelle E. Gray,David Vicente,David Planchard,Luis Paz-Ares,Johan Vansteenkiste,Marina Chiara Garassino,Rina Hui,Xavier Quantin,Andreas Rimner,Yi-Long Wu,M. Özgüroĝlu,Ki Hyeong Lee,Terufumi Kato,Maike de Wit,Takayasu Kurata,Martin Reck,Byoung Chul Cho,Suresh Senan,Jarushka Naidoo,Helen Mann,Michael Newton,Piruntha Thiyagarajah,Scott J. Antonia +24 more
TL;DR: These updated analyses demonstrate robust and sustained OS and durable PFS benefit with durvalumab after chemoradiotherapy, establishing a new benchmark for standard of care in this setting.
Journal ArticleDOI
Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study
James Chih-Hsin Yang,Sang We Kim,Dong Wan Kim,Jong Seok Lee,Byoung Chul Cho,Jin Seok Ahn,Dae H. Lee,Tae Min Kim,Jonathan W. Goldman,Ronald B. Natale,Andrew P. Brown,Barbara Collins,Juliann Chmielecki,Karthick Vishwanathan,Karthick Vishwanathan,Ariadna Mendoza-Naranjo,Myung-Ju Ahn +16 more
TL;DR: Osimertinib showed meaningful therapeutic efficacy in the CNS and a manageable safety profile at 160 mg once daily in patients with EGFRm NSCLC and LM and the adverse event and PK profiles were consistent with previous reports for osimert inib.
Journal ArticleDOI
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Justin F. Gainor,Giuseppe Curigliano,Dong Wan Kim,Dae Ho Lee,Benjamin Besse,Christina S. Baik,Robert C. Doebele,Philippe A. Cassier,Gilberto Lopes,Daniel Shao-Weng Tan,Elena Garralda,Luis Paz-Ares,Byoung Chul Cho,Shirish M. Gadgeel,Michael Thomas,Stephen V. Liu,Matthew H. Taylor,Aaron S. Mansfield,Viola W. Zhu,Corinne Clifford,Hui Zhang,Michael Palmer,Jennifer Green,Christopher D. Turner,Vivek Subbiah +24 more
TL;DR: The ARROW study as discussed by the authors evaluated the safety, tolerability, and antitumour activity of pralsetinib, a highly potent, oral, selective RET inhibitor, in patients with RET fusion-positive NSCLC.
Journal ArticleDOI
Activation of IL-6R/JAK1/STAT3 Signaling Induces de novo Resistance to Irreversible EGFR Inhibitors in Non-Small Cell Lung Cancer with T790M Resistance Mutation
Sun Mi Kim,Oh-Joon Kwon,Yun Kyoung Hong,Joo Hang Kim,Flavio Solca,Sang Jun Ha,Ross A. Soo,James G. Christensen,Ji Hyun Lee,Byoung Chul Cho +9 more
TL;DR: It is suggested that IL-6R/JAK1/STAT3 signaling can be a potential therapeutic target to enhance the efficacy of irreversible EGFR TKIs in patients with EGFR GFR T790M.
Journal ArticleDOI
Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
Delvys Rodriguez-Abreu,Melissa Lynne Johnson,Maen A. Hussein,Manuel Cobo,Anjan Jayantilal Patel,Nevena Milica Secen,Ki Hyeong Lee,Bartomeu Massuti,Sandrine Hiret,James Chih-Hsin Yang,Fabrice Barlesi,Dae Ho Lee,Luis Paz-Ares,Robert W. Hsieh,Karen Miller,Namrata Patil,Patrick Twomey,Amy V. Kapp,Raymond D. Meng,Byoung Chul Cho +19 more
TL;DR: The immunomodulatory receptor TIGIT is a novel inhibitory immune checkpoint present on activated T cells and NK cells in multiple cancers, including NSCLC, and in a phase I study it is proposed that this checkpoint acts as an “inhibitory checkpoint” to halt cell reprograming.